4-硝基苯咪唑 | 10597-52-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 4-硝基苯咪唑
• 中文别名: 4(7)-硝基苯并咪唑；4-硝基-1H-苯并咪唑
• 英文名称: 4-nitro-benzimidazole
• 英文别名: 4-nitro-1H-benzo[d]imidazole；4-Nitro-1H-benzimidazole
• CAS: 10597-52-1
• 化学式: C₇H₅N₃O₂
• mdl: MFCD00220143
• 分子量: 163.136
• InChiKey: NEJMFSBXFBFELK-UHFFFAOYSA-N

物化性质

• 熔点：
  238-239 °C
• 沸点：
  475.7±18.0 °C(Predicted)
• 密度：
  1.525±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4(7)-Nitrobenzimidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4(7)-Nitrobenzimidazole
CAS number: 10597-52-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5N3O2
Molecular weight: 163.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-硝基苯咪唑 在 N,O-双三甲硅基乙酰胺 、 三氟甲磺酸三甲基硅酯 、 氨 、 对甲苯磺酸 作用下， 以 甲醇 、 丙酮 、 乙腈 为溶剂， 反应 23.0h， 生成 ((3aR,4R,6R,6aR)-2,2-dimethyl-6-(4-nitro-1H-benzo[d]imidazol-1-yl)tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol
  参考文献：
  名称：

  5'-（（（（Z）-4-氨基-2-丁烯基）甲基氨基）-5'-脱氧腺苷（MDL 73811或AbeAdo）的类似物的合成和评估–具有抗锥虫活性的S-腺苷甲硫氨酸脱羧酶抑制剂

  摘要：

  我们描述了我们为改善基于机制的多胺生物合成酶S-腺苷甲硫氨酸脱羧酶（AdoMetDC）的自杀抑制剂的药代动力学特性而做出的努力，这对于负责人类非洲锥虫病（HAT）的真核寄生虫布鲁氏锥虫的生存至关重要。前导化合物5'-（（（（Z）-4-氨基-2-丁烯基）甲基氨基）-5'-脱氧腺苷（1，也称为MDL 73811或AbeAdo，在HAT的淋巴模型中以低剂量具有疗效，但由于血脑屏障渗透性差，在HAT的CNS期小鼠模型中未显示出明显的作用。因此，我们制备并评估了一系列在氨基丁烯基侧链，5'-胺，核糖和嘌呤片段上有修饰的类似物。尽管我们从这个全面的数据集中获得了有价值的结构活性见解，但我们并没有在保持中枢化合物1的强抗寄生虫活性和代谢稳定性的同时改善中枢神经系统渗透的前景。

  DOI：

  10.1016/j.bmc.2017.07.063
• 作为产物：
  描述：

  2,6-二硝基苯胺 在 sodium sulfide 、 碳酸氢钠 作用下， 以 水 为溶剂， 生成 4-硝基苯咪唑
  参考文献：
  名称：

  包含两个AgI离子的连续金属介导碱基对

  摘要：

  通过使用金属介导的碱基对将过渡金属离子掺入核酸已被证明是对这些生物分子进行位点特异性功能化的有前途的策略。我们在这里报告了包括1，3-dideaza-2'-deoxyadenosine和thymidine的Ag +介导的Hoogsteen型碱基对的形成。通过使腺嘌呤的沃森-克里克边缘失功能，禁止形成规则的碱基对。亚甲基部分额外取代腺嘌呤的N3氮原子增加了环外氨基的碱性。因此，1,3-二氮杂氮腺嘌呤和胸腺嘧啶能够将两个Ag +离子掺入其Hoogsteen型碱基对中（与之相比，一个Ag +离子与1-deazaadenine和胸腺嘧啶成对）。我们通过结合实验技术（UV和圆二色性（CD）光谱学，动态光散射和质谱法）证明，这种类型的碱基对与不同的序列环境兼容，可以连续用于DNA双螺旋中。当使用含有交替的嘌呤和嘧啶核苷的序列时，观察到最稳定的双链体。进行了色散校正的密度泛函理论计算，以深入了解双重金属

  DOI：

  10.1002/chem.201002944
• 作为试剂：
  描述：

  N2 (dimethylamino)-4-chloro-3-nitro-5-trifluoromethyl-1,2-phenylenediamine 、 (2,6-二硝基-4-三氟甲基苯基)-肼 在 钯 4-硝基苯咪唑 、 silica gel 作用下， 以 乙醇 为溶剂， 反应 26.0h， 生成 7-nitro-6-chloro-1-dimethylamino-2-methyl-5-trifluoromethylbenzimidazole
  参考文献：
  名称：

  5-Trifluoromethyl-7-nitrobenzimidazoles

  摘要：

  公式为##SPC1##的苯并咪唑，其中R.sub.1和R.sub.2代表至少一个可以选择性地被取代的烷基基团，X为低级烷氧基或卤素，R.sub.1也可以是二烷基氨基，而R.sub.2可以是卤素。这些化合物可用作除草剂制备的中间体。

  公开号：

  US03954788A1

文献信息

• N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
  申请人：——

  公开号：US20020165241A1

  公开（公告）日：2002-11-07

  Compounds represented by Formula (I): 1 or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

  由化学式（I）表示的化合物及其药学上可接受的盐，可作为NMDA NR2B拮抗剂，用于缓解疼痛。
• Certain substituted ureas, as modulators of kinase activity
  申请人：Mitchell A. Scott

  公开号：US20060270702A1

  公开（公告）日：2006-11-30

  Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.

  本文提供了从化合物1的化学实体和药用可接受的盐、溶剂化合物、螯合物、非共价复合物和前药中选择的某些化学实体。本文还提供了包括至少一种化学实体和一种或多种药用可接受载体（如载体、辅料和赋形剂）的药物组合物。公开了治疗对血管生成激酶调节敏感的某些疾病和疾病的方法，包括向这些患者施用至少一种化学实体的有效量以减少疾病或疾病症状的方法。这些疾病包括癌症，包括乳腺肿瘤、子宫内膜癌、结肠癌和颈部鳞状细胞癌。治疗方法包括将至少一种化学实体作为单一活性剂或将至少一种化学实体与一种或多种其他治疗剂结合使用的方法。一种用于确定样品中是否存在血管生成激酶的方法，包括将样品与至少一种化学实体接触在允许检测血管生成激酶活性的条件下，检测血管生成激酶活性水平，并从中确定样品中是否存在血管生成激酶。
• THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
  申请人：Lemieux Rene M.

  公开号：US20150031627A1

  公开（公告）日：2015-01-29

  Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

  提供的方法是治疗一种由IDH1/2突变等位基因特征性存在的癌症，包括向需要此治疗的患者施用此处描述的化合物。
• [EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS MÉTHODES D'UTILISATION
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2015010297A1

  公开（公告）日：2015-01-29

  Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

  提供的方法是治疗一种由IDH1/2突变等位基因特征性存在的癌症，包括向需要此治疗的患者施用此处描述的化合物。
• [EN] SUBSTITUTED PIXYL PROTECTING GROUPS FOR OLIGONUCLEOTIDE SYNTHESIS<br/>[FR] GROUPES SUBSTITUES DE PROTECTION DE PIXYLE DESTINES A UNE SYNTHESE D'OLIGONUCLEOTIDES
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2005077966A1

  公开（公告）日：2005-08-25

  The present invention describes an improved hydroxyl protecting group of formula (1), wherein R2 and R7 are specified substituents and Q is O, S, NR10 or N(C=O)R10.

  本发明描述了一种改进的羟基保护基团，其化学式为（1），其中R2和R7是指定的取代基，Q为O、S、NR10或N(C=O)R10。